Sartorius Stedim Biotech S.A. (0RG8)
LSE
207.50
-8.00 (-3.71%)
Closed
Oct 8, 2026
Day's Range
207.50217.20
52 wk Range
150.00225.00
Financial Statements - 0RG8 - Sartorius Stedim Biotech S.A.
Revenue
2.96B▲ 6.7%
Net Income
266.00M▲ 49.0%Net Margin 9.0%
EBITDA
846.90M▲ 19.8%
Free Cash Flow
299.00M▼ 37.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.96B | 2.78B | 2.77B | 3.49B | 2.88B | 1.91B |
| Cost of Goods | 1.62B | 1.57B | 1.54B | 1.67B | 1.33B | 906.75M |
| Gross Profit | 1.34B | 1.20B | 1.23B | 1.81B | 1.55B | 1B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 539.40M | 397.60M | 467.40M | 1.05B | 883M | 503.44M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 373.20M | 219.20M | 401.90M | 1.13B | 646.70M | 460.69M |
| Income Tax | 107.30M | 40.70M | 89.20M | 250.50M | 232.40M | 122.09M |
| Net Income | 266M | 178.50M | 312.70M | 879.90M | 414.30M | 338.59M |
| EPS Basic | 2.73 | 1.81 | 3.37 | 9.51 | 4.5 | 3.64 |
| EPS Diluted | 2.73 | 1.81 | 3.37 | 9.51 | 4.5 | 3.64 |
| Basic Shares Outstanding | 97.29M | 96.74M | 92.16M | 92.16M | 92.17M | 92.17M |
| Diluted Shares Outstanding | 97.29M | 96.74M | 92.16M | 92.16M | 92.17M | 92.17M |
| Ebit | 512.70M | 368.80M | 518.90M | 1.14B | 657.10M | 467.51M |
| Ebitda | 846.90M | 706.90M | 691.90M | 1.20B | 1.03B | 600.78M |
| Net Income Continuous Operations | 373.20M | 219.20M | 401.90M | 1.13B | 646.70M | 460.69M |
| Minority Interests | -300K | -3.40M | -2.40M | -3.80M | 100K | -2.66M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
